Blockade of Glioma Proliferation through Allosteric Inhibition of JAK2
View/ Open
65-Ye-2013b.pdf (7.472Mb)
Access Status
Full text of the requested work is not available in DASH at this time ("restricted access"). For more information on restricted deposits, see our FAQ.Author
He, Kunyan
Chan, Chi-Bun
Xiao, Ge
Liu, Xia
Tucker-Burden, Carol
Wang, Liya
Mao, Hui
Lu, Xiang
McDonald, Frank E.
Fan, Qi-Wen
Weiss, William A.
Sun, Shi-Yong
Brat, Daniel J.
Ye, Keqiang
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1126/scisignal.2003900Metadata
Show full item recordCitation
He, Kunyan, Qi Qi, Chi-Bun Chan, Ge Xiao, Xia Liu, Carol Tucker-Burden, Liya Wang, et al. 2013. “Blockade of Glioma Proliferation through Allosteric Inhibition of JAK2.” Science Signaling 6 (283) (July 9): ra55. doi:10.1126/scisignal.2003900. http://dx.doi.org/10.1126/scisignal.2003900.Abstract
The gene that encodes the epidermal growth factor receptor (EGFR) is frequently overexpressed or mutated in human cancers, including glioblastoma. However, the efficacy of EGFR-targeted small-molecule inhibitors or monoclonal antibodies in glioblastomas that also have mutation or deletion of the gene encoding phosphatase and tensin homolog (PTEN) has been modest. We found that EGFR signaling was blocked by a small molecule (G5-7) that selectively inhibited Janus kinase 2 (JAK2)–mediated phosphorylation and activation of EGFR and STAT3 (signal transducer and activator of transcription 3) by binding to JAK2, thereby decreasing the activity of downstream signaling by mTOR (mammalian target of rapamycin) and inducing cell cycle arrest. G5-7 inhibited the proliferation of PTEN-deficient glioblastoma cell lines harboring a constitutively active variant of EGFR (U87MG/EGFRvIII) and human glioblastoma explant neurosphere cultures, but the drug only weakly inhibited the proliferation of either glioblastoma cell lines that were wild type for EGFR and stably transfected with PTEN (U87MG/PTEN) or normal neural progenitor cells and astrocytes. Additionally, G5-7 reduced vascular endothelial growth factor (VEGF) secretion and endothelial cell migration and induced apoptosis in glioblastoma xenografts, thereby suppressing glioblastoma growth in vivo. Furthermore, G5-7 was more potent than EGFR or JAK2 inhibitors that interfere with either ligand or adenosine 5'-triphosphate (ATP) binding at impeding glioblastoma cell proliferation, demonstrating that this allosteric JAK2 inhibitor may be an effective clinical strategy.Other Sources
http://www.ncbi.nlm.nih.gov/pubmed/23838182Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:13350305
Collections
- HMS Scholarly Articles [17918]
Contact administrator regarding this item (to report mistakes or request changes)